目的:为中国药物经济学研究的完善、发展提供借鉴和思路。方法:采用文献计量学方法,对国外药物经济学文献进行统计分析。结果:获得3894篇文献,分布在996个期刊,主要期刊是Value in Health和Pharmacoeconomics;研究人员集中于欧美地区,...目的:为中国药物经济学研究的完善、发展提供借鉴和思路。方法:采用文献计量学方法,对国外药物经济学文献进行统计分析。结果:获得3894篇文献,分布在996个期刊,主要期刊是Value in Health和Pharmacoeconomics;研究人员集中于欧美地区,主要研究类型为定量研究,主要分析方法为成本-效果分析;主要研究常见病、多发病用药和贵重药,以及全身性或重大疾病。结论:国外药物经济学研究在研究类型、分析方法、研究内容等方面都可以给我们启发和借鉴。展开更多
This paper presented detailed information about the timeline of development of drug risk management in FDA. The time process was divided into three stages： the launch of laws and regulations of drug risk management, ...This paper presented detailed information about the timeline of development of drug risk management in FDA. The time process was divided into three stages： the launch of laws and regulations of drug risk management, pre-market approval and post-market safety supervision, adverse drug reaction and risk communication. To address the problems existing in drug risk management in China, suggestions to further and improve the development of drug risk management are proposed.展开更多
文摘目的:为中国药物经济学研究的完善、发展提供借鉴和思路。方法:采用文献计量学方法,对国外药物经济学文献进行统计分析。结果:获得3894篇文献,分布在996个期刊,主要期刊是Value in Health和Pharmacoeconomics;研究人员集中于欧美地区,主要研究类型为定量研究,主要分析方法为成本-效果分析;主要研究常见病、多发病用药和贵重药,以及全身性或重大疾病。结论:国外药物经济学研究在研究类型、分析方法、研究内容等方面都可以给我们启发和借鉴。
文摘This paper presented detailed information about the timeline of development of drug risk management in FDA. The time process was divided into three stages： the launch of laws and regulations of drug risk management, pre-market approval and post-market safety supervision, adverse drug reaction and risk communication. To address the problems existing in drug risk management in China, suggestions to further and improve the development of drug risk management are proposed.
